Cargando…
The Challenge and Opportunity of NTRK Inhibitors in Non-Small Cell Lung Cancer
With the development of targeted therapy, non-small cell lung cancer (NSCLC) patients could have more treatment choices if target mutation presents. The neurotrophic tropomyosin receptor kinase (NTRK) has a low prevalence in NSCLC, roughly around 0.5%. FDA had approved two first generation NTRK inhi...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954929/ https://www.ncbi.nlm.nih.gov/pubmed/35328336 http://dx.doi.org/10.3390/ijms23062916 |